TY - JOUR A1 - Schneider, Rudolf A1 - Korsak, B. A1 - Almeida, G. M. A1 - Rocha, S. A1 - Pereira, C. A1 - Mendes, N. A1 - Osorio, H. A1 - Pereira, P. M. A1 - Rodrigues, J. M. M. A1 - Sarmento, B. A1 - Tome, J. P. C. A1 - Oliveira, C. T1 - Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer N2 - Gastric cancer (GC) is the 3rd deadliest cancer worldwide, due to limited treatment options and late diagnosis. Human epidermal growth factor receptor-2 (HER2) is overexpressed in similar to 20% of GC cases and anti-HER2 antibody trastuzumab in combination with conventional chemotherapy, is recognized as standard therapy for HER2-positive metastatic GC. This strategy improves GC patients' survival by 2-3 months, however its optimal results in breast cancer indicate that GC survival may be improved. A new photoimmunoconjugate was developed by conjugating a porphyrin with trastuzumab (Trast: Porph) for targeted photodynamic therapy in HER2-positive GC. Using mass spectrometry analysis, the lysine residues in the trastuzumab structure most prone for porphyrin conjugation were mapped. The in vitro data demonstrates that Trast: Porph specifically binds to HER2-positive cells, accumulates intracellularly, co-localizes with lysosomal marker LAMP1, and induces massive HER2-positive cell death upon cellular irradiation. The high selectivity and cytotoxicity of Trast: Porph based photoimmunotherapy is confirmed in vivo in comparison with trastuzumab alone, using nude mice xenografted with a HER2-positive GC cell line. In the setting of human disease, these data suggest that repetitive cycles of Trast: Porph photoimmunotherapy may be used as an improved treatment strategy in HER2-positive GC patients. KW - Photoimmunotherapy KW - Photoimmunoconjugate KW - Gastric cancer PY - 2017 DO - https://doi.org/10.1002/ijc.30844 SN - 0020-7136 VL - 141 IS - 7 SP - 1478 EP - 1489 PB - International Journal of Cancer AN - OPUS4-43315 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - JOUR A1 - Pereira, P.M.R. A1 - Korsak, B. A1 - Sarmento, B. A1 - Schneider, Rudolf A1 - Fernandes, R. A1 - Tomé, J.P.C. T1 - Antibodies armed with photosensitizers: from chemical synthesis to photobiological applications N2 - Targeting photosensitizers to cancer cells by conjugating them with specific antibodies, able to recognize and bind to tumor-associated antigens, is today one of the most attractive strategies in photodynamic therapy (PDT). This comprehensive review updates on chemical routes available for the preparation of photo-immunoconjugates (PICs), which show dual chemical and biological functionalities: photo-properties of the photosensitizer and the immunoreactivity of the antibody. Moreover, photobiological results obtained with such photo-immunoconjugates using in vitro and in vivo cancer models are also discussed. KW - Therapeutische Antikörper KW - Krebstherapie KW - Photodynamische Therapie KW - Konjugate KW - Porphyrine KW - Phthalocyanine KW - Chlorine KW - Kopplungsmethoden PY - 2015 DO - https://doi.org/10.1039/c4ob02334j SN - 1477-0520 SN - 1477-0539 VL - 13 IS - 9 SP - 2518 EP - 2529 PB - RSC CY - Cambridge AN - OPUS4-32734 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -